CSF2 and cancer: We found that Montanide ISA-51 and Granulocyte-macrophage colony-stimulating factor (GM-CSF) were the two most widely used adjuvants in cancer vaccines (Figure 5A), and they also appeared most frequently in high clinical response results (P = 6.83e-19 and 0.045, respectively, Figures 5A, B).